2017
Association Between Functional Polymorphism in Neuropeptide Y Gene Promoter rs16147 and Resilience to Traumatic Stress in US Military Veterans.
Watkins LE, Han S, Krystal JH, Southwick SM, Gelernter J, Pietrzak RH. Association Between Functional Polymorphism in Neuropeptide Y Gene Promoter rs16147 and Resilience to Traumatic Stress in US Military Veterans. The Journal Of Clinical Psychiatry 2017, 78: e1058-e1059. PMID: 29099554, DOI: 10.4088/jcp.17l11646.Peer-Reviewed Original Research
2009
NPY moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane‐exposed adults
Amstadter AB, Koenen KC, Ruggiero KJ, Acierno R, Galea S, Kilpatrick DG, Gelernter J. NPY moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane‐exposed adults. Depression And Anxiety 2009, 27: 270-275. PMID: 20037921, PMCID: PMC2879267, DOI: 10.1002/da.20648.Peer-Reviewed Original ResearchConceptsGeneralized anxiety disorderNeuropeptide YEpidemiologic sampleGAD diagnosisHurricane exposureAnxiety disordersRandom digit dial proceduresHigh hurricane exposureFlorida Hurricane StudyFunctional single nucleotide polymorphismsNPY rs16147NPY expressionOutcome measuresGene-environment interactionsStressor exposureBuccal DNA samplesSingle nucleotide polymorphismsGAD symptomsRs16147AdultsStructured interviewsExposureDiagnosisRiskDisorders
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity
1989
Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y
Berrettini W, Garrick N, Nurnberger J, Simmons-Alling S, Gelernter J, Gold P, Rubinow D, Murphy D. Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. Biological Psychiatry 1989, 26: 623-630. PMID: 2790099, DOI: 10.1016/0006-3223(89)90087-5.Peer-Reviewed Original ResearchConceptsIntravenous infusionMicrograms/Central nervous system neurotransmittersAcute pharmacological challengePharmacological challenge paradigmsAcute intravenous infusionSerial CSF samplesDose-time interactionUseful clinical toolNormal human subjectsCholinergic agonist physostigmineCerebrospinal fluid neuropeptidesCSF NPYPhysostigmine infusionStimulus-induced responsesIntravenous physostigmineCSF levelsCSF cathetersCSF neuropeptidesNeuropeptide changesPharmacological challengeCSF samplesClinical toolRhesus monkeysPhysostigmine